3/ Don't forget "immortal time bias" - pts can only get 2nd malignancies if #MMsm is controlled enough and they are alive. In MAMMOTH (albeit not quite the same), median survival only 8.6 months. In FDA statement, time to MDS/AML was >1yr since CAR…
RT @LouisWilliamsMD: https://t.co/JiUfgvflYl. This cleverly named look at outcomes in CD-38 refractory disease (they’re dismal) from 2019 h…
https://t.co/JiUfgvflYl. This cleverly named look at outcomes in CD-38 refractory disease (they’re dismal) from 2019 has come up a few times offline recently and can be useful in contextualizing the impact of new treatments in this space #mmsm @End_myeloma
@mtmdphd @bdermanmd Agree 100% - working on one of these, also this from some great colleagues (s/o @myeloma_doc_com, Ujj Gandhi who is too smart to be on twitter) sheds light on therapy sequencing and thus optimal first relapse therapy: https://t.co/I…